The primary analysis in this trial will be comparison of the QuIC-A scores in the experimental group after exposure to the enhanced informed consent materials in addition to the standard PIS (standard of care) as compared with the control group after exposure to the standard PIS (standard of care). We will include all randomised patients for whom we have data on the initial QuIC-A (the primary endpoint). The patients recruited to the GBM cohort will not be included in the primary analysis.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.